Adicet Bio to Participate in Upcoming Investor Conferences
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company
discovering and developing first-in-class allogeneic gamma delta T
cell therapies for cancer and other diseases, today announced that
company management will participate in two virtual investor
conferences in January.
Details of the events are as follows:
H.C. Wainwright Bioconnect 2021 ConferenceThe
presentation will be available for on-demand viewing starting
January 11, 2021 at 6:00 AM ET.
B. Riley Securities' Oncology Investor
ConferenceFireside chat on January 20, 2021 at 3:30 PM
A replay of the pre-recorded H.C. Wainwright presentation can be
accessed on January 11, 2021 in the investors section of the
Company’s website, and a live webcast of the B. Riley presentation
can be accessed in the same section of the Company’s
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and
developing allogeneic gamma delta T cell therapies for cancer and
other diseases. Adicet is advancing a pipeline of “off-the-shelf”
gamma delta T cells, engineered with chimeric antigen receptors and
T cell receptor-like antibodies to enhance selective tumor
targeting, facilitate innate and adaptive anti-tumor immune
response, and improve persistence for durable activity in patients.
For more information, please visit our website
Adicet Bio., Inc.Investor and Media
Janhavi MohiteStern Investor Relations,